Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis.
Saved in:
| Title: | Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. |
|---|---|
| Authors: | Gbesemete D; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Ramasamy MN; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Ibrahim M; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Hill AR; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Raud L; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Ferreira DM; Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Guy J; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Dale AP; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Laver JR; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Coutinho T; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Science, University of Southampton, Southampton, UK., Reed TAN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Babbage G; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Weissfeld L; WCG Clinical, Princeton, NJ, USA., Lang W; WCG Clinical, Princeton, NJ, USA., Locht C; Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr., Samal V; ILiAD Biotechnologies, Weston, FL, USA., Goldstein P; ILiAD Biotechnologies, Weston, FL, USA., Solovay K; ILiAD Biotechnologies, Weston, FL, USA., Rubin K; ILiAD Biotechnologies, Weston, FL, USA., Noviello S; ILiAD Biotechnologies, Weston, FL, USA., Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. |
| Source: | The Lancet. Microbe [Lancet Microbe] 2025 Dec; Vol. 6 (12), pp. 101211. Date of Electronic Publication: 2025 Dec 01. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
